![](https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg)
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple ...
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously published in the Journal of Clinical Oncology Also …